Alkermes vs ImmunityBio
Alkermes (ALKS), health care, and ImmunityBio (IBRX), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
Alkermes is worth $7.7B on the stock market and ImmunityBio $6.6B: Alkermes is valued at 16% more. Alkermes's operating margin in its latest fiscal year was 17.2% and ImmunityBio's -226%. Over the past year Alkermes's share price has moved +59.0% and ImmunityBio's +185%.
Key facts
- Alkermes market value
- $7.7B
- ImmunityBio market value
- $6.6B
- Alkermes revenue
- $1.5BFY to 2025-12-31
- ImmunityBio revenue
- $113.3MFY to 2025-12-31
- Superinvestors holding both
- 0
Market values as of .
| Measure | Alkermes | ImmunityBio |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size | ||
| Market cap | $7.7Bhigher | $6.6Blower |
| Revenue | $1.5Bhigher | $113.3Mlower |
| Earnings | $241.7Mhigher | -$351.4Mlower |
| Employees | 2,050higher | 684lower |
| Total assets | $2.5Bhigher | $501.9Mlower |
| Valuation | ||
| P/E | — | — |
| P/S | 5.2lower | 58.4higher |
| P/B | — | — |
| Dividend yield | — | 0.00% |
| Profitability | ||
| Operating margin | 17.2%higher | -226%lower |
| Balance sheet | ||
| Net assets | $1.8Bhigher | -$500.5Mlower |
| Total liabilities | $667.7Mlower | $1Bhigher |
| Total debt | — | — |
| Cash on hand | $388.6Mhigher | $88.3Mlower |
| Price change | ||
| Today | -1.98%lower | +4.01%higher |
| 1 year | +59.0%lower | +185%higher |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Both (0)
None of the tracked investors.
Alkermes only (4)
ImmunityBio only (0)
None of the tracked investors.
Percentages are each holding's share of that investor's reported portfolio. Who owns ALKS
More on Alkermes
Further comparisons
Alkermes against its closest peers
ImmunityBio against its closest peers
Learn
Questions and answers
Which is bigger, Alkermes or ImmunityBio?
By market value, Alkermes is the larger: $7.7B against $6.6B for ImmunityBio. By revenue in its latest fiscal year, Alkermes is the larger: $1.5B against $113.3M for ImmunityBio.
Which has the higher operating margin?
Alkermes: 17.2%, against -226% for ImmunityBio. Operating margin is operating income as a share of revenue in the latest fiscal year.
Which superinvestors own both Alkermes and ImmunityBio?
None of the tracked superinvestors holds both in their latest 13F filing. 4 hold Alkermes and 0 hold ImmunityBio.
Cite this page
Funkfolio, “Alkermes vs ImmunityBio”, data as of 17 November 2026. https://funkfolio.com/compare/alks-vs-ibrx
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.